ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Duloxetine repositioning: Investigation of antifungal and antibiofilm activity against fluconazole-sensitive and resistant Candida Spp. strains.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increase in fungal infections, the limited therapeutic arsenal, and the emergence of resistance pose a global health problem. Candida spp. stand out as opportunistic pathogens that cause superficial and invasive diseases. Thus, the search for new therapeutic alternatives, such as drug repositioning, is necessary. Duloxetine (DUL), a serotonin-norepinephrine reuptake inhibitor antidepressant used to treat depression, has demonstrated antifungal activity and potentiates the effects of conventional antifungals in vitro. The objective of this study is to evaluate the in vitro activity of duloxetine (DUL) against resistant Candida spp. strains. To this end, the minimum inhibitory concentration (MIC) of DUL alone and in combination with conventional antifungals was determined in order to evaluate the type of interaction between them, as well as the minimum fungicidal concentration (MFC). The activity of DUL against mature and developing biofilms was evaluated, in addition to the possible antifungal mechanism of action. DUL showed MICs of 16 to 128 µg/mL with a fungicidal action profile, and when combined there was synergistic interaction with amphotericin B (AMB). In biofilms, DUL exhibited antibiofilm activity and enhanced AMB activity against developing, but not mature, biofilms. Mechanism of action analysis showed that DUL promoted oxidative stress, evidenced by increased reactive oxygen species (ROS) production, reduced GSH levels, mitochondrial depolarization, and phosphatidylserine externalization, suggesting the activation of the apoptotic pathway as a possible mechanism of cell death. The pro-oxidant effects of DUL were evident in C. albicans strains deficient in antioxidant defenses (cap1Δ and gpx3Δ) compared to the wild-type strain. DUL exhibited antibiofilm activity and enhanced AMB activity against developing, but not mature, biofilms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.